
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma 05 October 2020
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
For our Danish readers, please enjoy the Life Science section of Berlingske today 15th Sept 2020, where... Read more
European start-ups selected as part of a joint initiative with J&J and the US government Did you... Read more
MC2 Therapeutics, a commercial stage pharmaceutical company focused on innovative topical therapies for... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
Are you a start-up and early-stage MedTech company interested in commercializing your pro... Read more
Unilabs Denmark, a unit of the leading European diagnostic services provider, has launched a larg... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the develop... Read more